US Stock MarketDetailed Quotes
IPSC Century Therapeutics
- 1.210
- -0.030-2.42%
Close Nov 22 16:00 ET
- 1.200
- -0.010-0.83%
Post 18:23 ET
102.89MMarket Cap-661P/E (TTM)
1.270High1.200Low529.97KVolume1.220Open1.240Pre Close653.47KTurnover1.37%Turnover RatioLossP/E (Static)85.03MShares5.51052wk High0.53P/B46.86MFloat Cap1.14052wk Low--Dividend TTM38.72MShs Float32.899Historical High--Div YieldTTM5.65%Amplitude1.140Historical Low1.233Avg Price1Lot Size
Century Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -107.58%-28.33M | -41.98%-27.33M | -3.52%-30.25M | -728.72%-88.35M | -14.51%-26.23M | 43.69%-13.65M | 24.68%-19.25M | -133.68%-29.22M | 115.79%14.05M | 5.93%-22.91M |
| Net income from continuing operations | 4.57%-31.22M | 6.26%-31.21M | 10.24%-28.06M | -4.38%-136.67M | -24.35%-39.4M | -6.41%-32.72M | -7.43%-33.29M | 16.66%-31.26M | -36.64%-130.93M | -12.37%-31.68M |
| Depreciation and amortization | -1.55%3.3M | 7.05%3.46M | 10.94%3.23M | 54.55%13.04M | 25.16%3.55M | 20.76%3.35M | 93.88%3.23M | 150.69%2.91M | 125.19%8.44M | 170.03%2.84M |
| Other non cash items | 185.13%372K | -212.58%-2.46M | 326.10%1.54M | -157.10%-1.1M | 30.94%804K | -181.23%-437K | -253.11%-787K | -358.33%-682K | 59.64%1.93M | 86.06%614K |
| Change In working capital | -122.78%-2.78M | -82.56%713K | -127.40%-9.05M | -92.43%9.38M | -212.35%-2.91M | 2,849.15%12.18M | 753.65%4.09M | -103.30%-3.98M | 4,531.36%123.95M | 213.68%2.59M |
| -Change in prepaid assets | -206.66%-721K | 1,278.70%1.27M | -2,021.88%-3.4M | -35.12%667K | -81.80%259K | 206.62%676K | 86.40%-108K | -115.49%-160K | 132.31%1.03M | 860.96%1.42M |
| -Change in payables and accrued expense | -78.70%1.48M | -249.54%-2.12M | 57.63%-2.61M | -271.96%-3.09M | -952.69%-5.27M | 184.87%6.93M | 1,689.89%1.42M | -130.45%-6.16M | -132.12%-831K | -145.38%-501K |
| -Change in other current liabilities | -157.98%-2.74M | -19.26%2.33M | -156.90%-2.19M | 162.82%13.82M | 14.92%2.37M | 560.70%4.72M | 9.50%2.88M | 2,627.63%3.84M | 12,924.39%5.26M | 1,051.15%2.06M |
| -Change in other working capital | -434.46%-791K | -677.78%-770K | 43.00%-855K | -101.70%-2.02M | 32.15%-268K | 92.95%-148K | 92.20%-99K | -101.23%-1.5M | 15,013.52%118.49M | -413.49%-395K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -107.58%-28.33M | -41.98%-27.33M | -3.52%-30.25M | -728.72%-88.35M | -14.51%-26.23M | 43.69%-13.65M | 24.68%-19.25M | -133.68%-29.22M | 115.79%14.05M | 5.93%-22.91M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 829.55%39.2M | -585.57%-33.86M | -63.17%11.54M | 565.66%61.13M | 535.36%18.6M | -81.39%4.22M | -44.29%6.97M | 171.16%31.34M | 95.60%-13.13M | 79.26%-4.27M |
| Net PPE purchase and sale | 125.27%825K | 94.11%-265K | 89.20%-539K | 55.12%-13.74M | 84.37%-980K | 66.72%-3.27M | 56.97%-4.5M | -22.72%-4.99M | 31.95%-30.6M | 62.51%-6.27M |
| Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Net investment purchase and sale | 412.88%38.37M | -309.09%-23.99M | -66.75%12.08M | 328.40%74.87M | 881.60%19.58M | -76.96%7.48M | -50.06%11.47M | 190.89%36.33M | 106.90%17.48M | 151.40%2M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 829.55%39.2M | -585.57%-33.86M | -63.17%11.54M | 565.66%61.13M | 535.36%18.6M | -81.39%4.22M | -44.29%6.97M | 171.16%31.34M | 95.60%-13.13M | 79.26%-4.27M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -9.00%273K | 660.41%56.7M | 3,961.38%18.2M | -135.81%-9.73M | -474.74%-356K | 118.98%300K | -21,177.08%-10.12M | -98.33%448K | -93.50%27.16M | -10.38%95K |
| Net issuance payments of debt | --0 | ---- | ---- | ---10.24M | --0 | --0 | ---- | ---- | --0 | --0 |
| Net common stock issuance | -9.00%273K | 45,623.39%56.7M | 3,961.38%18.2M | -98.10%516K | -474.74%-356K | 118.98%300K | 158.33%124K | -98.33%448K | -87.75%27.16M | 14.46%95K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -9.00%273K | 660.41%56.7M | 3,961.38%18.2M | -135.81%-9.73M | -474.74%-356K | 118.98%300K | -21,177.08%-10.12M | -98.33%448K | -93.50%27.16M | -10.38%95K |
| Net cash flow | ||||||||||
| Beginning cash position | -33.31%44.29M | -45.06%48.79M | -42.83%49.3M | 48.28%86.24M | -49.45%57.29M | -42.13%66.42M | -30.48%88.81M | 48.28%86.24M | 109.76%58.16M | 10.02%113.33M |
| Current changes in cash | 221.99%11.14M | 79.91%-4.5M | -119.95%-512K | -231.55%-36.94M | 70.53%-7.98M | -535.49%-9.13M | -72.39%-22.39M | -96.31%2.57M | -7.73%28.08M | 39.61%-27.09M |
| End cash Position | -3.24%55.43M | -33.31%44.29M | -45.06%48.79M | -42.83%49.3M | -42.83%49.3M | -49.45%57.29M | -42.13%66.42M | -30.48%88.81M | 48.28%86.24M | 48.28%86.24M |
| Free cash flow | -62.75%-27.53M | -16.20%-27.6M | 10.01%-30.79M | -516.75%-102.08M | 6.74%-27.21M | 50.33%-16.91M | 34.05%-23.75M | -141.37%-34.21M | 87.65%-16.55M | 28.97%-29.18M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data